OTCMKTS:USRM

U.s. Stem Cell Stock Insider Trading

> Biotechnology

Buy USRM

*Your capital is at risk

$0.0001

+0 (+0%)

At Close: Jun 22, 2026

U.S. Stem Cell Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 416.77M and sold 0 USRM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	0
● Buy	416.77M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Aug 17, 2017 Buy	Common Stock P-Purchase	Murphy William P Jr Director	Director	1 799 614 Value: $49.8K
Aug 07, 2017 Buy	Common Stock, par value $. 001 per share	Knutson Gregory Director	Director	0 Value: $0
Aug 07, 2017 Buy	Common Stock, par value $. 001 per share	Knutson Gregory Director	Director	0 Value: $0
Aug 07, 2017 Buy	Stock Option (right to buy)	Knutson Gregory Director	Director	625 000 Value: $20.4K
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Comella Kristin C Chief Scientific Officer	Officer	1 500 000 Value: $48.9K
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Comella Kristin C Chief Scientific Officer	Officer	7 500 000 Value: $244.5K
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Tomas Mike CEO & President	CEO / President	1 500 000 Value: $48.9K
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Tomas Mike CEO & President	CEO / President	15 000 000 Value: $489.0K
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Tomas Mike CEO & President	CEO / President	15 000 000 Value: $489.0K
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Tomas Mike CEO & President	CEO / President	1 500 000 Value: $48.9K
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Comella Kristin C Chief Scientific Officer	Officer	7 500 000 Value: $244.5K
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Comella Kristin C Chief Scientific Officer	Officer	1 500 000 Value: $48.9K
Aug 07, 2017 Buy	Stock Option (right to buy)	Knutson Gregory Director	Director	625 000 Value: $20.4K
Aug 07, 2017 Buy	Common Stock, par value $. 001 per share	Knutson Gregory Director	Director	0 Value: $0
Aug 07, 2017 Buy	Common Stock, par value $. 001 per share	Knutson Gregory Director	Director	0 Value: $0
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Murphy William P Jr Director	Director	1 500 000 Value: $48.9K
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Borman Mark P Director	Director	1 500 000 Value: $48.9K
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Anderson Sheldon T. Director	Director	1 500 000 Value: $48.9K
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Anderson Sheldon T. Director	Director	1 500 000 Value: $48.9K
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Borman Mark P Director	Director	1 500 000 Value: $48.9K
Aug 07, 2017 Buy	Stock Option (right to buy) A-Award	Murphy William P Jr Director	Director	1 500 000 Value: $48.9K
Mar 29, 2017 Buy	Common Stock M-Exempt	Murphy William P Jr Director	Director	1 748 947 Value: $58.6K
Mar 29, 2017 Buy	Common Stock M-Exempt	Murphy William P Jr Director	Director	1 748 947 Value: $58.6K
Mar 06, 2017 Buy	Common Stock P-Purchase	Murphy William P Jr Director	Director	1 200 000 Value: $24.0K
Mar 06, 2017 Buy	Common Stock P-Purchase	Murphy William P Jr Director	Director	1 200 000 Value: $24.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT U.S. STEM CELL, INC.

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's...

Read Full Profile Here